DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

(2020) Yonghan He et al.   Nature Communications

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

(2019) Rumani Singh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The curcumin analog EF24 is a novel senolytic agent

(2019) Wen Li et al.   Aging-US

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

(2018) Samuel Y. Ng et al.   Nature Communications

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

(2018) Raphael Koch et al.   BLOOD

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

(2017) Ian Churcher   JOURNAL OF MEDICINAL CHEMISTRY

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

(2017) D T Saenz et al.   LEUKEMIA

Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies

(2017) Steven Grant   LEUKEMIA & LYMPHOMA

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia

(2017) Sonali P. Barwe et al.   SEMINARS IN ONCOLOGY

Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy

(2016) Nobumichi Ohoka et al.   CURRENT CANCER DRUG TARGETS

Chemical genetics approaches for selective intervention in epigenetics

(2016) Andrew C Runcie et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project

(2016) A. M. Perry et al.   HAEMATOLOGICA

Microenvironmental cues for T-cell acute lymphoblastic leukemia development

(2016) Diana Passaro et al.   IMMUNOLOGICAL REVIEWS

Induced protein degradation: an emerging drug discovery paradigm

(2016) Ashton C. Lai et al.   NATURE REVIEWS DRUG DISCOVERY

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project

(2016) A. M. Perry et al.   HAEMATOLOGICA

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

(2015) Michael Zengerle et al.   ACS Chemical Biology

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL

(2015) Ashton C. Lai et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Prime time for PROTACs

(2015) Raymond J Deshaies   Nature Chemical Biology

Catalytic in vivo protein knockdown by small-molecule PROTACs

(2015) Daniel P Bondeson et al.   Nature Chemical Biology

Phthalimide conjugation as a strategy for in vivo target protein degradation

(2015) G. E. Winter et al.   SCIENCE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

How I treat the peripheral T-cell lymphomas

(2014) A. J. Moskowitz et al.   BLOOD

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

(2014) Aksana Kaefer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH